<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00171808</url>
  </required_header>
  <id_info>
    <org_study_id>CFEM345ADE08</org_study_id>
    <secondary_id>EudraCT-Number: 2004-003886-34</secondary_id>
    <nct_id>NCT00171808</nct_id>
  </id_info>
  <brief_title>Letrozole in the Treatment of Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer</brief_title>
  <acronym>deFEND</acronym>
  <official_title>Phase II Study on Letrozole in Patients With Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      In Western industrialized countries, endometrial cancer is the most common malignancy of the&#xD;
      female reproductive tract.&#xD;
&#xD;
      The general therapy options are surgery, radiotherapy, chemotherapy and endocrine therapy.&#xD;
      This trial will investigate the efficacy and safety of letrozole in the treatment of advanced&#xD;
      or recurrent hormone receptor-positive endometrial cancer .&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical response rate (partial response PR and complete response CR) according to RECIST at least once during the treatment period</measure>
    <time_frame>until disease progression</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>until disease progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>until disease progression</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>Letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <arm_group_label>Letrozole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Presence of histologically proven adenocarcinoma or adenosquamous carcinoma of the&#xD;
             endometrium&#xD;
&#xD;
          -  Presence of advanced or recurrent endometrial cancer, FIGO stage I-IV, incurable with&#xD;
             surgery and/or radiation therapy&#xD;
&#xD;
          -  Documented ER and/or PgR positive endometrial cancer. Hormone receptor positivity is&#xD;
             defined according to routine practice at each participating laboratory.&#xD;
&#xD;
          -  Patient must be postmenopausal defined as&#xD;
&#xD;
               -  Age ≥55 years.&#xD;
&#xD;
               -  Age &lt;55 but no spontaneous menses for at least 1 year.&#xD;
&#xD;
               -  Age &lt;55 and spontaneous menses within the past 1 year, but currently amenorrheic&#xD;
                  (e.g., spontaneous or secondary to hysterectomy), and with postmenopausal&#xD;
                  gonadotrophin levels (luteinizing hormone and follicle stimulating hormone levels&#xD;
                  &gt;40 IU/L) or postmenopausal estradiol levels (&lt;5 ng/dL) or according to the&#xD;
                  definition of &quot;postmenopausal range&quot; for the laboratory involved.&#xD;
&#xD;
               -  Bilateral oophorectomy&#xD;
&#xD;
               -  Radiation menopause&#xD;
&#xD;
          -  Presence of measurable disease (by clinical/radiological examination - according to&#xD;
             RECIST criteria : minimum indicator lesion size : 20 mm (unless spiral CT scan in&#xD;
             which case &gt; 10 mm)&#xD;
&#xD;
          -  ECOG performance status of 0, 1 or 2&#xD;
&#xD;
          -  Adequate bone marrow function (WBC ≥ 3.5 x 1'000'000'000/L and platelets ≥ 100.0 x&#xD;
             1'000'000'000/L) and hemoglobin &gt; 10.0 g/dl&#xD;
&#xD;
          -  Adequate renal function (creatinine &lt; 120 µmol/L) and hepatic function (bilirubin &lt; 25&#xD;
             µmol/L, AST (SGOT &lt; 60 U/L)&#xD;
&#xD;
          -  Minimum life expectancy of at least 6 months&#xD;
&#xD;
          -  Patients who are accessible for treatment and follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of non-measurable disease only&#xD;
&#xD;
          -  Other concomitant anti-cancer treatment (except external radiation treatment [XRT] for&#xD;
             symptomatic metastatic lesions if other assessable untreated lesions are present)&#xD;
&#xD;
          -  Prior treatment with aromatase inhibitors or anti-estrogens (up to one previous&#xD;
             progestational hormone therapy regimen for recurrent disease is permitted)&#xD;
&#xD;
          -  Clear cell or papillary serous histology, uterine sarcomas, mixed Mullerian tumors&#xD;
             (MMT) and/or adenosarcomas&#xD;
&#xD;
          -  Other concurrent malignant disease with the exception of cone-biopsied in situ&#xD;
             carcinoma of the cervix uteri, or adequately treated basal or squamous cell carcinoma&#xD;
             of the skin, or other curable cancers e.g. Hodgkin's disease or non-Hodgkin lymphoma&#xD;
             (NHL), provided 5 years have elapsed from completion of therapy, and there has been no&#xD;
             recurrence&#xD;
&#xD;
          -  Known central nervous system (CNS) metastases, bilateral diffuse lymphangiosis&#xD;
             carcinoma of the lung (&gt;50 % of lung involvement, or dyspnea at rest requiring&#xD;
             supplemental oxygen therapy), evidence of metastases estimated as more than a third of&#xD;
             the liver as defined by sonogram and/or CT scan&#xD;
&#xD;
          -  Uncontrolled endocrine disorders such as diabetes mellitus, confirmed hypo- or&#xD;
             hyperthyroidism, Cushing's Syndrome, Addison's disease (treated or untreated)&#xD;
&#xD;
          -  Unstable angina and uncontrolled cardiac disease&#xD;
&#xD;
          -  Treatment with other investigational drugs (drugs not marketed for any indication)&#xD;
             within the past 30 days and/or the concomitant use of investigational drugs&#xD;
&#xD;
          -  A history of non-compliance to medical regimens and patients who, in the opinion of&#xD;
             the investigator, are unlikely to cooperate fully during the study&#xD;
&#xD;
          -  Inability to swallow pills&#xD;
&#xD;
        Additional protocol-defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmeceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ebersberg, Germany</name>
      <address>
        <city>Celle</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heidelberg, Germany</name>
      <address>
        <city>Ebersberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ebersberg, Germany</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Celle, Germany</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tuebingen, Germany</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Muenchen, Germany</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Muenchen, Germany</name>
      <address>
        <city>Muenchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oberaudorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tuebingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hannover, Germany</name>
      <address>
        <city>Wolfsburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://journals.lww.com/ijgc/Documents/ESGO%202011%20Abstracts.pdf</url>
    <description>Abstract Page 39 (ISSN 1048891X)</description>
  </link>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>November 16, 2016</last_update_submitted>
  <last_update_submitted_qc>November 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endometrial Cancer</keyword>
  <keyword>Aromatase inhibitor</keyword>
  <keyword>Advanced or recurrent</keyword>
  <keyword>hormone receptor positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

